Background: There is an epidemic of overweight and obesity in America and Western societies for which there is no obvious solution. Pharmaceuticals are on the market to address this condition but are occasionally associated with serious adverse effects. These observations suggest other therapeutic modalities might be helpful. The current approach is a nutrient-based formulation designed to assist in weight reduction.
INTRODUCTION
Obesity is currently one of the most prevalent problems affecting health in the United States. [ 1 ] A staggering 90 million Americans are now considered obese. Obesity related conditions such as glucose intolerance, hyperinsulinemia, non-insulin dependent diabetes mellitus (NIDDM), hypertension, dyslipidemia and vascular disorders are responsible for increasing morbidity and mortality in western society.[ 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 ] Not only are individuals affected but also, because of the associated health care costs, governments are being fiscally impacted by the current epidemic of obesity. [ 11 ] Ten years ago, one in four Americans was considered obese; now that figure is one in three. There are a number of contributing factors, yet there is no obvious resolution. Clearly, our bodies are not well adapted to our current dietary and lifestyle choices. These observations provide a mandate for the creation of unique new therapeutic approaches to mitigate the accumulation of adipose tissue.
The purpose of the current study is to pursue the application of these concepts. A composition containing biotin, Lcarnitine, aspartic acid, chromium, and Garcinia cambogia extract was formulated. The relative amounts and ratios of the individual ingredients were chosen to maximally stimulate hepatic fatty acid oxidation, inhibit lipid synthesis and induce metabolic thermogenic activity. The primary outcome being investigated in this clinical trial was that of facilitated weight loss.
MATERIALS AND METHODS

DESIGN
The trial design was prospective, randomized, placebocontrolled and double blind in nature. The duration was six weeks. Equal numbers of subjects were randomized into the active and placebo arms. Each was required to sign informed consent. Approval was received from the Triad Institutional Review Board in Springfield, Illinois. Participants were recruited from local physician practices and from the general population. They each were required to satisfy the inclusionary and exclusionary criteria and to pass compliance testing. All subjects were treated equally and confidentiality was assured. They were free to leave the study at any time. Each subject had been essentially sedentary, weight stable and without recent dietary changes prior to initiation of the study.
Diet counseling was provided and consisted of recommendations to restrict intake of refined carbohydrates and hydrogenated fats. No caloric guidelines were included. Lean protein sources and fruits and vegetables were emphasized. However, to maintain their daily routine, participants chose and prepared their meals at home. Exercise was performed and consisted of 20 minutes of light aerobic training three times per week and ten minutes of light resistance training two times per week at the trial center facility. Compliance was confirmed through biweekly contacts. All participants were required to attend meetings prior to initiation of the study and every other week for the duration of the clinical trial. These reinforced the dietary and exercise components of the study, disseminated information, and provided support for the continued participation of the subjects. Each participant took one dose of active product or placebo in a glass of water twice per day. One dose of active product consisted of: biotin-600mcg, chromium chloride-400mcg, aspartic acid-4g, Garcinia cambogia fruit extract (50% hydroxycitrate)-500mg, and L-carnitine tartrate-10mg.
Weight, limb and waist circumference were measured at baseline and at two weekly intervals throughout the study. Vital signs (HR, BP) were monitored sequentially throughout the duration of the trial. Baseline and off-study lab values were performed. These included CBC, liver profile, electrolytes, BUN, creatinine, glucose, cholesterol and triglycerides.
STATISTICAL ANALYSIS
Twenty-eight subjects were randomized into each of two groups at the start of the trial. Twenty-two and twenty-one respectively (product, placebo) completed the second visit, and twenty and seventeen completed the third follow-up visit. The loss rates were similar between the two groups and potential biases were not observed.
All statistical analyses were conducted with the Statistical Analysis Systems software (SAS; Cary, NC). Tests for differences of means for continuous data were conducted using paired or unpaired t-tests, while chi-square tests were utilized for categorical data. Fisher's exact two-tail chisquare was used for comparisons with small cells.
RESULTS
There were no statistically significant differences between the product and placebo groups regarding clinically important baseline factors or demographic parameters. These included age, baseline weight, behavioral variables (smoking, alcohol, caffeine) and health risk profiles. (See Table I ) Weight loss over the entire six-week course of the study was steady and uniform. Weight loss per week per individual on placebo was 1.0 pound. For the active product, the same figure was 1.72 pounds. Thus, the nutritional product was responsible for an average net weight loss of 0.72 pounds per week over placebo. (See Table II ) The arm and waist circumference data revealed no statistically significant differences. (See Tables III and IV) There were no adverse reactions attributable to the nutrient composition. There was no statistically significant change in heart rate or blood pressure in either group. There was a downward-trend in serum total cholesterol level. The value in the active arm was 27 mg/dl lower than in the placebo group (p=0.06). (See Table V ) Otherwise, there were no significant differences or changes noted in lab values either between arms of the study or over the course of the study in either group. 
DISCUSSION
The clinical trial documented a clear weight loss effect of the nutrient composition. It also appeared to be well tolerated. These results are of interest because several of the ingredients have shown inconsistent weight loss activity when used as stand alone agents. This suggests the presence of significant synergistic interactions when they are used in combination and administered in specific ratios. The active sites involving each of the nutritional components in association with their respective metabolic effects suggest several possible mechanistic actions.
The liver is the organ most likely mediating the activity of the nutrient composition. It has the biochemical apparatus that enables it to either oxidize or esterify fatty acids and synthesize or break down glucose. Modulation of the enzyme glucokinase (GK) by the nutrient mixture is postulated as playing a key role in its overall activity. This enzyme is present in liver but is absent from adipose tissue and skeletal muscle. Any changes induced in the esterification/oxidation (E/O) ratio would alter hepatic tissue TG levels with potentially beneficial impact upon hepatic insulin sensitivity. [ 12 , 13 ] Due to the ability to activate ketogenesis and dissociate it from hepatocyte respiratory chain activity, the ratio of pyruvate dehydrogenase to pyruvate carboxylase activity (PDH/PC) may be manipulated. [ 14 ] This ratio represents the relative effect, catabolic or anabolic, the liver has on glucose metabolism at any moment. Hepatic ketogenesis has anabolic effects upon glucose metabolism. The converse is also true. This implies that enhanced FA oxidation in liver is associated with increased gluconeogenesis and subsequent expansion of hepatic glycogen stores. These actions typify the reciprocal effect the liver has upon the metabolism of these two key nutrients.
Specific nutrients are known to possess utility in modulating certain biochemical steps involving these specific pathways. Stanko et al were the first to utilize pyruvate in such a setting. They substituted a composition containing equal amounts of pyruvate and dihydroxyacetonephosphate (DHAP) on an energetically equivalent basis for a portion of dietary carbohydrate intake in rats with fatty livers.
[ 15 ] Marked decreases in hepatic TG content as well as a fall in total carcass lipid content were identified. Subsequent observers have confirmed these findings. [ 16 , 17 ] This approach has also been shown to reduce weight gain and feed efficiency in obese Zucker rats and to promote weight and fat loss in obese women. [ 18 , 19 ] From these observations, they were able to postulate hepatic anti-obesity activity for their pyruvate/DHAP combination. Thermogenic actions as mediators of these weight loss effects were suggested, but precise explanations were lacking. As will be seen, the ostensible mechanism responsible for this activity is likely related to the unique ability of pyruvate to act as a source of intramitochondrial oxaloacetate (OAA) via the pyruvate carboxylase (PC) reaction. [ 20 ] This provides the critical metabolic link between fat oxidation and glucose synthesis. Aspartate, one of the ingredients in the current composition, acts as a direct metabolic precursor for generation of intramitochondrial OAA via a transamination reaction.
[ 21 ] (See Figure I) To promote better understanding of not only the pyruvate/DHAP activity, but to incorporate the ingredients of the current weight loss mixture into a more complete hepatic weight loss paradigm involves dissection of the plethora of beneficial interactions the nutrient components manifest. J.D. McGarry has provided the biochemical framework into which the current presentation was embedded.[ 22 , 23 , 24 ] To facilitate understanding and provide overview for the following discussion, the anticipated benefits provided by the ingredients in the nutrient mix include enhanced FA oxidation (while restraining esterification) and increased hepatic glucose storage (while limiting glucose oxidation). The anticipated consequences emanating from these changes include decrement in respiratory quotient (RQ), diminution of tissue TG level, and weight loss.
Central factors regulating control of hepatic lipid utilization involve modulation of carnitine palmitoyl transferase-1 (CPT1) activity. [ 23 ] This enzyme represents the ratecontrolling step in the pathway of long chain FA oxidation. (See Figure I ) Intracellular hepatocyte carnitine and malonyl CoA concentrations play key regulatory roles via their effects on CPT1. Carnitine is the co-factor for CPT1 and is usually present in subsaturating amounts in the liver. Enhancement of FA oxidation and ketogenesis in liver is accompanied by a proportional elevation of tissue carnitine content. [ ACC is modulated by both transcriptional and posttranscriptional controls, which collectively contribute to the mRNA and protein concentrations as well as enzymatic activity. Upregulation occurs under conditions of enhanced glycolytic flux and a high insulin/glucagon (I/G) ratio. [ 27 ] Augmentation of dietary protein intake tends to increase the serum glucagon level. Factors which improve IS are expected to promote a fall in insulin level. Restriction of refined and high glycemic index carbohydrate intake amplifies this effect. Trivalent chromium has the ability to promote clinical insulin sensitivity. [ 28 ] In vitro studies have shown it can improve insulin response in muscle and adipose tissue. Chromium supplementation in women with gestational diabetes lowered serum insulin levels. By it's beneficial action on IS associated with a fall in serum insulin levels and a decrease in I/G ratio, chromium acts to lower ACC activity, producing subsequent beneficial effects upon malonyl CoA levels. The combination of the hepatic catabolic action upon fat combined with its anabolic effect upon glucose alters the composition of the fuel mix. Enhanced contribution from fat and diminished glucose input act to lower the RQ. Since increased fat oxidation is intimately coupled with a fall in FA esterification, hepatic TG content and subsequent VLDL production are expected to fall. These changes would be expected to improve hepatic insulin sensitivity. Because the upregulation of FA oxidation utilizes a "pull" rather than a "push" mechanism upon adipose tissue, serum FA and TG levels should fall.
CONCLUSION
The nutrient composition evaluated in the current limited weight loss trial was well tolerated and produced significant weight loss. There was a fall of 27 mg/dl of total cholesterol over the six week interval of the study. These results provide the foundation for subsequent investigations designed to analyze potential mechanisms of action. 
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